AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
David C Turner

David C Turner

GlaxoSmithKline - Needham / United Kingdom
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4370457
-
person_outline David C Turner's MOST POPULAR ARTICLES
1-) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study Neuro-oncology 19 (8), 1135-1144, 2017
2-) Crenolanib is active against models of drug-resistant FLT3-ITD− positive acute myeloid leukemia Blood, The Journal of the American Society of Hematology 122 (22), 3607-3615, 2013
3-) Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance Clinical Cancer Research 24 (23), 5841-5849, 2018
4-) Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer Annals of Oncology 27 (7), 1291-1298, 2016
5-) Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma Cancer cell 25 (4), 516-529, 2014